Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy

• Jonathan Z. Li ,

  * E-mail: Jli22@partners.org

  Affiliation Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Brad Chapman,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Patrick Charlebois,

  Affiliation Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Oliver Hofmann,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Brian Weiner,

  Affiliation Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Alyssa J. Porter,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Reshmi Samuel,

  Affiliations Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Virology, University of KwaZulu-Natal, National Health Laboratory Service, Durban, South Africa

  ⨯
• Saran Vardhanabhuti,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Lu Zheng,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
• Joseph Eron,

  Affiliation Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United States of America

  ⨯
• Babafemi Taiwo,

  Affiliation Division of Infectious Diseases, Northwestern University, Chicago, Illinois, United States of America

  ⨯
• Michael C. Zody,

  Affiliation Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Matthew R. Henn,

  Affiliation Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

  ⨯
• Daniel R. Kuritzkes,

  Affiliation Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Winston Hide,

  Affiliation Harvard School of Public Health, Boston, Massachusetts, United States of America

  ⨯
•  [ ... ],
• and the ACTG A5262 Study Team

  ¶Membership of the ACTG A5262 Study Team is provided in the Acknowledgments.

  ⨯
• [ view all ]
• [ view less ]